Microbot Medical Inc (NASDAQ: MBOT)’s stock price has soared by 0.41 in relation to previous closing price of 2.45. Nevertheless, the company has seen a loss of -0.40% in its stock price over the last five trading days. globenewswire.com reported 2025-06-17 that HINGHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, announced that it has been granted a critical patent in China by the China National Intellectual Property Administration (CNIPA), a key step in the Company’s global IP expansion strategy.
Is It Worth Investing in Microbot Medical Inc (NASDAQ: MBOT) Right Now?
MBOT has 36-month beta value of 1.14. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MBOT is 35.98M, and currently, short sellers hold a 22.39% ratio of that float. The average trading volume of MBOT on June 26, 2025 was 2.58M shares.
MBOT’s Market Performance
MBOT stock saw a decrease of -0.40% in the past week, with a monthly decline of -8.89% and a quarterly a decrease of 61.84%. The volatility ratio for the week is 4.99%, and the volatility levels for the last 30 days are 6.37% for Microbot Medical Inc (MBOT). The simple moving average for the past 20 days is -3.07% for MBOT’s stock, with a 50.73% simple moving average for the past 200 days.
Analysts’ Opinion of MBOT
Many brokerage firms have already submitted their reports for MBOT stocks, with H.C. Wainwright repeating the rating for MBOT by listing it as a “Buy.” The predicted price for MBOT in the upcoming period, according to H.C. Wainwright is $26 based on the research report published on January 13, 2020 of the previous year 2020.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MBOT reach a price target of $12, previously predicting the price at $10. The rating they have provided for MBOT stocks is “Buy” according to the report published on December 24th, 2019.
Ladenburg Thalmann gave a rating of “Buy” to MBOT, setting the target price at $1.75 in the report published on January 31st of the previous year.
MBOT Trading at -2.52% from the 50-Day Moving Average
After a stumble in the market that brought MBOT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.22% of loss for the given period.
Stock Fundamentals for MBOT
The total capital return value is set at -0.32. Equity return is now at value -66.48, with -61.02 for asset returns.
Based on Microbot Medical Inc (MBOT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -67.25.
Currently, EBITDA for the company is -11.35 million with net debt to EBITDA at 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.19.
Conclusion
To put it simply, Microbot Medical Inc (MBOT) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
